Trauma Induced Coagulopathy

Eduardo Gonzalez
Hunter B. Moore
Ernest E. Moore
Editors

Springer

Trauma Induced Coagulopathy

Eduardo Gonzalez
Hunter B. Moore • Ernest E. Moore
Editors

Trauma Induced Coagulopathy

Springer

Editors
Eduardo Gonzalez
Department of Surgery and Trauma Research Center
University of Colorado School of Medicine
Aurora, CO, USA

Ernest E. Moore
Professor of Surgery
Vice-Chair of Research
Department of Surgery and Trauma Research Center
University of Colorado School of Medicine and Denver Health Medical Center
Aurora, CO, USA

Editor in-Chief
Journal of Trauma and Acute Care Surgery
Denver, CO, USA

Hunter B. Moore
Department of Surgery and Trauma Research Center
University of Colorado School of Medicine
Aurora, CO, USA

ISBN 978-3-319-28306-7 ISBN 978-3-319-28308-1 (eBook)
DOI 10.1007/978-3-319-28308-1

Library of Congress Control Number: 2016934440

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG Switzerland

Foreword

The absence of hemorrhage control identified as "trauma-induced coagulopathy" is a major contributor to mortality following potentially survivable trauma. This comprehensive and timely text integrates reviews on the biology of blood coagulation, including the plasmin–fibrin/fibrinolysis system, by describing human and animal studies of trauma-induced coagulopathy. These latter studies describe the role of platelets, the endothelium, the fibrinolytic system, the complement system, and inflammation, as well as recent discoveries associated with damage-associated molecular pattern molecules (DAMP) in both hemostatic and thrombotic pathology.

These reviews are linked to practical descriptions of those technologies presently available for assessing trauma-induced coagulopathy in clinical scenarios and also summarize their limitations. The most current clinical studies describing the therapeutic intervention trials with red blood cells, platelets, cryoprecipitate, whole plasma, and plasma derivatives, as well as current concepts regarding antifibrinolytic agents are summarized. The hypercoagulable state seen following successful attenuation of bleeding after injury, which is either associated with the primary injury or a consequence of those therapies used to treat the original pathology, is also discussed in detail.

While no surrogate for human pathology in the study of trauma is completely adequate, both the animal models and numerical modeling procedures described in this monograph have been advanced as mechanisms for the transition of laboratory-based hypotheses to the evaluation and therapeutic intervention associated with trauma.

This book provides a catalyst to link laboratory research-based assets with the clinical expertise of surgeons and physicians. This interaction should yield the comprehensive studies required to develop therapeutic and diagnostic techniques to thoroughly understand and effectively treat trauma-induced coagulopathy.

Burlington, VT — Kenneth G. Mann

Preface

Like many good ideas in clinical medicine, trauma-induced coagulopathy was the product of a routine multidisciplinary research meeting. Two research fellows, Eduardo and Hunter, were presenting their experimental plans and remarked that their study backgrounds were based on literature from a variety of disciplines in diverse journals. They proposed compiling a collection of seminal papers from the experts in the field to assist those interested in coagulation research. The idea was further stimulated by frequent questions from our colleagues on the surgical intensive care unit rounds who wanted to understand the basis for our new concepts in coagulation management that were not available in surgical texts. As the process unfolded, it became clear that multiple classic papers were required for each concept. The collection soon became too large for practical distribution, and the next evolutionary step was to extract information from each contribution to generate a reference handbook. We ultimately recognized that the individual components of the coagulation system were simply too complex to relegate to a summary in a handbook. Thus, we agreed the most useful reference would be a text of chapters written by those conducting research in various fields related to coagulation.

Denver, CO, USA

Eduardo Gonzalez
Hunter B. Moore
Ernest E. Moore

Historical Perspective of Trauma Induced Coagulopathy

Keywords

History
Trauma
Coagulopathy
Transfusion
Plasmin
Platelets
Fibrinogen
Thrombelastography
Thromboelastometry

Injury is the second leading cause of death worldwide [1], and the third leading cause of mortality in the United States [2]. Despite advances in emergency medical systems and trauma care, deaths from injury have increased in the United States over the last decade [3]. In both the civilian [4] and military [5] settings, uncontrolled hemorrhage is the leading cause of preventable death after injury. In civilian studies, 80 % of deaths from hemorrhage occur within the first 24 h, at a median time of 2 h [4]. Consequently, there is intense interest worldwide in the pathogenesis of coagulopathic bleeding after injury and its early management. While there have been substantial insights, the words of Mario Stefanini in his address to the New York Academy of Medicine in 1954 [6] remain applicable today: "The ponderous literature on the subject of hemostasis could perhaps be considered a classical example of the infinite ability of the human mind for abstract speculation. For several years, the number of working theories of the hemostatic mechanisms greatly exceeded and not always respected the confirmed experimental facts. In recent years, however, the revived interest in this field has led to an accumulation of new findings, which has been almost too rapid for their orderly incorporation into a logical working pattern. As a result, we have rapidly gone from a state of orderly ignorance to one of confused enlightenment, from which we have not emerged as yet."

The evolution of our understanding of the complexities of coagulopathy associated with trauma has been, in large part, the result of collaboration between civilian and military researchers and clinicians. The earliest reports

of coagulopathy in injured patients were generated from military research teams, often including civilian consultants, during major wars. These novel observations would then intensify hemostasis research in civilian centers. Ultimately, the resulting findings improved coagulopathy management in subsequent conflicts, and primed the environment for making new observations. The specific contributions to our understanding of coagulopathy, however, are somewhat difficult to ascertain from World War I through Vietnam because the primary focus was on optimizing shock resuscitation at a time when plasma or whole blood was employed to replace acute blood loss [7]. Nonetheless, several landmark contributions are well recognized.

In 1916 the US National Research Council formed a Subcommittee on Traumatic Shock that collaborated with the British Medical Research Committee to study wounded soldiers in the front lines of France. Among them was Walton B. Cannon from Harvard, who was perplexed by the inconsistencies of the prevailing toxin theory of shock. Based on observations made on the battlefield in France during 1918 [8], Cannon wrote "…the heart, nervous system and other organs are suffering from an insufficient blood supply" and later admonished "if the pressure is raised before the surgeon is ready…blood that is sorely needed may be lost." Cannon documented experimentally that stress, i.e., epinephrine infusion into animals, provoked hypercoagulability followed by hypocoagulability [9]. Cannon also stated prophetically "…shock is a loss of homeostasis, and without homeostasis the patient does not survive." In 1936, based on Cannon's observations and his own research at Vanderbilt and Johns Hopkins, Alfred Blalock [10] concluded "the work of recent years has shown that shock is dependent on an inadequate supply of blood to the tissues, which may be brought about by the most diverse causes," i.e., hematogenic, neurogenic, vasogenic, and cardiogenic.

In the spring of 1940, with major victories established by Germany and Japan, the US involvement in the war appeared inevitable. Military experts recognized that bottled whole blood would be logistically impractical and enlisted the expertise of Edwin Cohen, a Harvard biochemist, to deconstruct blood in order to deliver its components to the battlefield [11]. Cohen was successful in purifying albumin as well as preparing plasma. At the onset of World War II, the National Research Council's Committee on Transfusion recommended that dried plasma—not blood—would be used if combat occurred outside the continental United States because it was easy to prepare and transport, whereas whole blood had to be typed, cross-matched, and refrigerated. Based on the legendary work of consultant Edward D. Churchill [12] in North Africa, who concluded, "wound shock is blood volume loss," the policy was changed to whole blood administration and implemented in Italy in 1943.

In 1952, the Board for the Study of the Severely Wounded systematically reviewed the cause of death in 186 war casualties. The report was dominated by the discovery of a new syndrome "post-traumatic renal failure" that was attributed to prolonged hypoperfusion. This observation ultimately led to a paradigm shift in resuscitation, incorporating crystalloid as a fundamental component of initial fluid administration [13]. Contemporary studies in civilian hospitals, based on observations in trauma and burn patients, reported a "severe bleeding tendency" implicating fibrinolysis [14, 15]. The plasmin–antiplasmin system had been well characterized at this point [16]. Alternatively,

others postulated the loss of a labile clotting factor in whole blood and recognized the key role of platelets in hemostasis [17, 18]. In 1954, Stefanini [6] noted that postinjury hemorrhage persisting despite surgical control of bleeding was variously referred to as medical bleeding, diffuse bleeding diathesis, post-transfusion bleeding disorder, and disseminated intravascular coagulation (DIC), reflecting a general lack of consensus in the pathophysiology.

During the Korean War, William Stone is credited with promoting Surgical Research Teams in the combat zone in Korea [19]. Scott and Crosby [20], representing one such team, reported that the prothrombin time (PT) was doubled in combat casualties while platelet count and fibrinogen were increased. They also speculated that the cause was due to a labile clotting factor during blood storage. Artz and Fitts [21] observed that severely injured soldiers in the Korean Conflict required both return of shed blood and crystalloid for optimal survival, inspiring the later seminal work of Tom Shires [22] defining the scientific basis for crystalloids.

After the Korean War, civilian studies implicated a number of causative factors responsible for bleeding associated with major surgery requiring transfusion, including DIC [23], fibrinolysis [24], compromised viability of platelets in stored blood [25], and the loss of the labile factors V and VIII during storage [26]. The initial response to experimental hemorrhagic shock was hypercoagulability, followed by a progressive state of hypocoagulability with decreases in factors V, VIII, IX, X, and XI along with reduced fibrinogen and platelets [27]. The early clinical studies in Baltimore further identified a third phase of hypercoagulability in those who survived the intermediate period of hypocoagulability [28]. The authors concluded that in surviving patients, the oscillatory pattern converges into a "dynamic homeostatic state," whereas, in non-survivors, "fluctuations exceeded safe limits and behaved like a runaway system."

Based on the compelling experimental work by Shires et al. [22], the major change in resuscitation strategy in Vietnam was the administration of large volumes of crystalloid. This policy virtually eliminated acute kidney dysfunction, but led to a new entity coined "Da Nang Lung" [29], later termed the acute respiratory distress syndrome (ARDS) as the civilian counterpart [30]. The first large study on coagulation disorders in combat casualties from Vietnam was reported by Simmons et al. [31]. In their comprehensive analysis of 244 injured soldiers, the authors concluded that there is "an initial phase of hypercoagulability followed by hypocoagulability and this seemed best explained by DIC. "Massive transfusion was accompanied by a dilutional coagulopathy compatible with factor levels in stored blood. Platelet levels fell, but PT, partial thromboplastin time (PTT), and fibrinogen levels were less affected. "Fresh whole blood partially counteracts this dilutional state, but is rarely necessary," concluded Simmons. Miller et al. [32] studied 21 patients requiring a massive transfusion in Vietnam. Significant coagulation defects were not evident until 20 units of stored blood were administered. A dilutional defect in platelets appeared to be the primary cause for bleeding, and this was reversed with fresh whole blood administration. Interestingly, they reported no evidence of DIC or fibrinolysis. In 1974, John A. Collins [33] systematically reviewed the problems associated with massive transfusion and offered these observations: [1] "Early complete replacement of

blood volume in the massively bleeding patient lessens the impact of exchange transfusion with stored blood," [2] "An intact circulation is a very good defense against the metabolic problems of massive transfusion," and [3] "Historically as new problems associated with massive transfusion have been defined, they have almost always been grossly overstated."

Coagulation research in civilian institutions in the early 1970s began to elucidate the molecular events resulting in thrombin generation as the common end product of the extrinsic and intrinsic clotting pathways [34, 35]. In the clinical arena, trauma surgeons recognized that controlling bleeding from the liver was a priority to improve survival following trauma, but much of the work concentrated on techniques to achieve mechanical hemostasis with some mention of packing when bleeding continued [36–38]. It was also noted that tissue disruption from blunt trauma appeared to be associated with more problematic bleeding than penetrating wounds, stimulating resurgent interest in DIC and subsequent pulmonary microemboli [39, 40]. In the later 1970s, trauma surgeons began to recognize that bleeding following massive transfusion with stored blood required supplemental clotting factors. This literature is confounded by the fact that blood banks began to implement blood component therapy [41], a policy change that unmasked the prevalence of a trauma-related coagulopathy. In 1979, our group [42] and others [43–45] observed that the majority of patients succumbing to liver injuries died of a coagulopathy, after surgical control of bleeding. We recommended pre-emptive fresh frozen plasma (FFP): "If the patients remain hypotensive after the second unit of blood, FFP should be administered then and with every fourth unit thereafter." Furthermore, we advocated fresh whole blood "…if bleeding persists despite normal PT, PTT, and bleeding times" [42]. Stimulated by these findings, we analyzed a group of patients who developed life-threatening coagulopathy with major vascular injuries and noted the compelling association of metabolic acidosis and hypothermia. Confirming the independent effects of acidosis and hypothermia on coagulation experimentally [46], we proposed the "bloody vicious cycle" in 1982 [47], which subsequently became known as the "lethal triad" and now is often referred to as "resuscitation-associated coagulopathy." The concept of truncating definitive repair of all injuries in coagulopathic patients in the operating room, to allow for correction of hypothermia, acidosis, and coagulopathy in the intensive care unit, was the fundamental basis of "damage control surgery" introduced by Harlan Stone et al. in 1983 [48]. In studying our coagulopathic injured patients in 1982 [47], we noted that higher ratios of FFP to stored blood were associated with improved survival and advocated presumptive FFP:blood administration of 1:4 in the emergency department. Charles Lucas and Anna Ledgerwood also conducted animal work that supported the concept of pre-emptive FFP during massive transfusion [49]. In the later 1980s [50], the Detroit General Group systematically studied coagulation abnormalities in patients requiring a massive transfusion of stored red blood cells (RBC) and postulated them to be secondary to consumption of factors, reflected in standard measures of coagulopathy, i.e., PT, PTT, and thrombin time (TT). Collectively, the coagulopathy associated with severe trauma was postulated to be secondary to both consumption and dilution of clotting factors. There was also considerable inter-

est in the early administration of platelets due to the long-term observation of deteriorating platelet numbers in stored blood, although clinical trials failed to confirm a benefit of pre-emptive platelet administration [51].

In the ensuing decade much of the clinical investigation centered on optimizing the use of damage control surgery for refractory coagulopathy [52–54]. Coagulation research during this period was further complicated by the practice of aggressive crystalloid resuscitation targeting supra-physiologic oxygen delivery, promulgated by William Shoemaker et al. [55]. This resulted in an epidemic of compartment syndromes, with much attention diverted to the urgent need to decompress the abdomen following protracted shock that required high volume crystalloid resuscitation [56]. In retrospect, most of the compartment syndromes and, to a significant extent, coagulopathies were generated by overzealous infusion of crystalloid driven by the subsequently disproven concept of supra-physiologic oxygen delivery [57]. There is no question that chasing oxygen delivery with Swan-Ganz catheters and attempting to correct metabolic acidosis with large volume crystalloid loading added a substantial component of dilutional coagulopathy [58].

The first decade of the twenty-first century perhaps represents the most significant insights gained into trauma-associated coagulopathy in modern history, and many of these investigators responsible are authors in this monograph. Progress was unquestionably inspired by the revolutionary concept of the cell-based model of coagulation proposed by Hoffman and Monroe [59] who emphasized the fundamental role of platelets as a platform for clotting factor assembly and thrombin generation on damaged endothelium. Paradoxically, these new insights led to the unbridled use of activated factor VII, which was ultimately proven unjustified [60, 61]. In 2003, MacLeod et al. [62] from the University of Miami made the observation that 28 % of severely injured patients had an elevated PT on arrival to the hospital, and this was associated with an increased risk of mortality. At the same time, Karim Brohi [63] from the Royal London Hospital reported that 24 % of severely injured patients had prolonged clotting times, and extended their analysis to demonstrate this abnormality was independent of fluid administration and, consequently, termed the syndrome the “acute coagulopathy of trauma” (ACOT). Stimulated by his observations on the ACOT in London, Brohi pursued a trauma research fellowship with Mitch Cohen and colleagues in San Francisco. Together, in 2007, this civilian research team provided compelling evidence that activation of protein C is an integral component of ACOT [64]. Shortly thereafter, Par Johansson [65] from Copenhagen added evidence of endothelial glycocalyx degradation, stimulating interest in the endotheliopathy of ACOT. Additional evidence has implicated the innate immune response in general [66], and neutrophils specifically [67] in the pathogenesis of ACOT.

Simultaneous with these provocative studies in civilian trauma centers, the military recognized coagulopathy as the most common source of preventable death in soldiers in the war in Iraq [68]. When confronted with this challenge, Hess and colleagues from the US Army [69] suggested the best solution was to replace the acute blood loss with a blood component formula that would replicate the whole blood lost, thus the genesis of the 1:1:1 concept. In 2007, Borgman et al. [70] reported the US military experience in Iraq suggesting a

survival benefit for soldiers resuscitated with an FFP:RBC ratio approaching 1:1 when they required a massive transfusion (10 units of red blood cells (RBC) in 24 h). This report was extrapolated to support the proposed "damage control resuscitation" concept with 1:1:1 as the centerpiece. Although the relative simplicity of this recommendation is appealing, this concept is not intuitively scientific and has prompted vigorous debate that continues today [71–74]. Ultimately these debates stimulated the National Institutes of Health (NIH) to conduct a Trans-Agency Coagulopathy in Trauma Workshop, held in Bethesda in April 2010. Out of this meeting came the consensus that the term "trauma-induced coagulopathy" (TIC) would be employed to describe what was previously referred to as ACOT.

Conspicuous among the many questions is whether platelets should be given empirically with the initial administration of FFP and RBC units in patients at risk for TIC. In contrast to platelets and plasma for first-line therapy in the United States, the European approach has been to load fibrinogen [75]. The current limitation in assessing platelet function for hemostasis has hampered resolution of this topic [76, 77]. Further is the debate of the optimal ratio of FFP:RBC units in the patient at risk for TIC. The only randomized trial to date failed to demonstrate a survival advantage of a 1:1 versus 1:2 FFP:RBC ratio when delivered with platelets [78, 79].

The role of systemic fibrinolysis in TIC has added another layer of controversy, which was largely overlooked until the widespread implementation of global viscoelastic assays of hemostasis in trauma care, such as thrombelastography (TEG) and thromboelastometry (ROTEM) [80–83]. Unfortunately, the CRASH-2 trial reported in 2010 [84] prompted indiscriminate use of tranexamic acid (TXA), until the limitations of this study were recognized [85, 86]. Subsequently, it was generally acknowledged in the United States that TXA should be reserved for selected populations until randomized trials clarify the indications, including its role in traumatic brain injury patients. Recently the elucidation of early fibrinolysis shutdown [87] has added to the concern of routine TXA administration. Finally, the issue of whether goal-directed therapy via viscoelastic assays such as TEG or ROTEM is superior to a fixed ratio approach is ongoing. A large retrospective study indicated that TEG-driven resuscitation was more effective than 1:1:1 approach [88], and our recent single-institution randomized study [89] indicated that TEG was more effective in guiding a massive transfusion protocol than conventional laboratory tests (PT, PTT, platelet count, and D-dimers). In 2013, driven by these ongoing controversies, the NIH funded a Trans-Agency Research Consortium for Trauma-Induced Coagulopathy (TACTIC) in collaboration with the Department of Defense (DOD) with the aim of elucidating the underlying mechanisms of TIC from "road to rehabilitation."

In sum, the need to define the scientific basis for blood component administration and regulation of fibrinolysis in the critically injured patient is as clear today as it was 60 years ago and, as optimistically articulated by Mario Stefanini [6], we are making substantive progress. "While the multiplicity of hypotheses and the conflict of experimental findings still deny us a firm theoretical basis for the interpretation of the mechanisms of hemostasis, the impact of the advances of the last 10 years on the diagnosis and management

of the bleeding patient has been staggering. New diagnostic tests have greatly increased the accuracy of the diagnosis; broader interest in the isolation of coagulation factors and of platelets points to more specific methods of treatment in the near future. One feels that, with the unending ferment of ideas and fervor of investigation in this field, great progress lies ahead."

Denver, CO, USA

Eduardo Gonzalez
Hunter B. Moore
Ernest E. Moore

References

1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle R, Danaei G, Ezzati M, Fahimi A, Flaxman D, et al. U.S. Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608.
2. Centers for Disease Control and Prevention. The Injury Fact Book. http://www.cdc.gov/Injury/Publications/Fact Book.
3. Rhee P, Joseph B, Pandit V, Aziz H, Vercruysse G, Kulvatunyou N, Friese RS. Increasing trauma deaths in the United States. Ann Surg. 2014;260:13–21.
4. Tisherman SA, Schmicker RH, Brasel KJ, Bulger EM, Kerby JD, Minei JP, Powell JL, Reiff DA, Rizoli SB, Schreiber MA. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium. Ann Surg. 2015;261:586–90.
5. Eastridge BJ, Hardin M, Cantrell J, Oetjen-Gerdes L, Zubko T, Mallak C, Wade CE, Simmons J, Mace J, Mabry R, Bolenbaucher R, Blackbourne LH. Died of wounds on the battlefield: causation and implications for improving combat casualty care. J Trauma. 2011;71:S4–8.
6. Stefanini M. Basic mechanisms of hemostasis. Bull NY Acad Med. 1954;30(4):239–77.
7. Hoyt DB. Blood and war-lest we forget. J Am Coll Surg. 2009;209:681–6.
8. Canon WB, Fraser J, Cowell EM. The preventive treatment of wound shock. JAMA. 1918;70:618–21.
9. Cannon WB, Gray H. Factors affecting the coagulation time of blood. II. The hastening or retarding of coagulation by adrenalin injections. Am J Physiol. 1914;34:232–7.
10. Blalock A. Shock and hemorrhage. Bull NY Acad Med. 1936;12:610–22.
11. Cohen EJ, Oncley JL, Strong LE, Hughes Jr WL, Armstrong SH. Chemical, clinical, immunological studies on the products of human plasma fractionation. 1. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:41.

12. Churchill ED. The surgical management of the wounded in the Mediterranean Theater at the time of the fall of Rome. Ann Surg. 1944;120:268–83.
13. Maier RV. A century of evolution in trauma resuscitation. J Am Coll Surg. 2014; 219:335–45.
14. MacFarlane RG, Biggs R. Observations on fibrinolysis; spontaneous activity associated with surgical operations and trauma. Lancet. 1946;14:862–4.
15. Tagnon HJ, Levenson SM. The occurrence of fibrinolysis in shock, with observations on the prothrombin time and the plasma fibrinogen during hemorrhagic shock. Am J Med Sci. 1946;211:88–96.
16. MacFarlane RG. Blood. 1948; 3:167–87.
17. Stefanini M. Activity of plasma labile factor in disease. Lancet. 1951;17: 606–10.
18. Stefanini M, Chatter, Jea JB. Studies on platelets. IV. A thrombocytopenic factor in normal human blood, plasma, or serum. Proc Soc Exp Biol Med. 1952;79:623–9.
19. Simeone FA. Studies of trauma and shock in man: William S. Stone's role in the military effort (1983 William S. Stone lecture). J Trauma. 1984;24:181–7.
20. Scott, R, Crosby WH. The hemostatic response to injury; a study of the Korean battle casualty. Ann Surg. 1955;141:347–56.
21. Artz CP, Fitts CJ. Replacement therapy in shock. J Trauma. 1962; 2:358–69.
22. McClelland RN, Shires GT, Baxter CR, Coln CD, Carrico J. Balanced salt solution in the treatment of hemorrhagic shock. Studies in dogs. JAMA. 1967;13;199:830–4.
23. Hardaway III RM, McKay DG. Disseminated intravascular coagulation: a cause of shock. Ann Surg. 1959;149:462–70.
24. Zucker MB, Siegel M, Cliffton EE, Bellville JW, Howland WS, Grossi CE. Generalized excessive oozing in patients undergoing major surgery and receiving multiple blood transfusions. J Lab Clin Med. 1957;50:849–61.
25. Baldini M, Costea N, Dameshek W. The viability of stored human platelets. Blood. 1960; 16:1669–92.
26. Rapaport SI, Ames SB, Mikkelsen S. The levels of antihemophilic globulin and proaccelerin in fresh and bank blood. Am J Clin Pathol. 1959;31:297–304.
27. Rutherford RB, West RL, Hardaway RM. Coagulation changes during experimental hemorrhagic shock. Clotting activity, contribution of splanchnic circulation and acidosis as controlled by THAM. Ann Surg. 1966;164:203–14.
28. Attar S, Kirby JR WH, Masaitis C, Mansberger AR, Cowley RA. Coagulation changes in clinical shock. I. Effect of hemorrhagic shock on clotting time in humans. Ann Surg. 1966;164:34–40.
29. Lewin I, Weil MH, Shubin H, Sherwin RJ. Pulmonary failure associated with clinical shock states. J Trauma. 1971;11:22–35.
30. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE Acute respiratory distress in adults. Lancet. 1967;12:319–23.

31. Simmons RL, Collins JA, Heisterkamp CA, Mills DE, Andren R, Phillips LL. Coagulation disorders in combat casualties. I. Acute changes after wounding. II. Effects of massive transfusion. III. Post-resuscitative changes. Ann Surg. 1969;169:455–82.
32. Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation defects associated with massive blood transfusions. Ann Surg. 1971;174:794–801.
33. Collins JA. Problems associated with the massive transfusion of stored blood. Surgery. 1974;75:274–95.
34. Esmon CT, Stenflo J, Suttie JW. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem. 1976;251:3052–6.
35. Mann KG, Heldebrant CM, Fass DN. Multiple active forms of thrombin. I. Partial resolution, differential activities, and sequential formation. J Biol Chem. 1971;246:5994–6001.
36. Lim RC, Knudson J, Steele M. Liver trauma: current method of management. Arch Surg. 1972;104:544–50.
37. Lucas CE, Ledgerwood AM. Prospective evaluation of hemostatic techniques for liver injuries. J Trauma. 1976;16:442–51.
38. Trunkey DD, Shires GT, Mc Clelland R. Management of liver trauma in 811 consecutive patients. Ann Surg. 1974;179:722–8.
39. Blaisdell FW, Stallone RJ. The mechanism of pulmonary damage following traumatic shock. Surg Gynecol Obstet. 1970;130:15–22.
40. Hardaway RM, Dixon RS, Foster EF, Karabin BL, Scifres FD, Meyers T. The effect of hemorrhagic shock on disseminated intravascular coagulation. Ann Surg. 1976;184:43–5.
41. Grindon AJ. The use of packed red blood cells. JAMA. 1976;26:235–389.
42. Elerding SC, Aragon GE, Moore EE. Fatal hepatic hemorrhage after trauma. Am J Surg. 1979;138:883–8.
43. Clagett GP, Olsen WR. Non-mechanical hemorrhage in severe liver injury. Ann Surg. 1978;187:369–74.
44. Levin A, Gover P, Nance FC. Surgical restraint in the management of hepatic injury: a review of the Charity Hospital Experience. J Trauma. 1978;18:399–404.
45. Svoboda JA, Peter ET, Dang CV, Parks SN, Ellyson JH. Severe liver trauma in the face of coagulopathy. A case for temporary packing and early reexploration. Am J Surg. 1982;144:717–21.
46. Dunn EL, Moore EE, Breslich DJ, Galloway WB. Acidosis induced coagulopathy. Surg Forum. 1979;XXX:471–3.
47. Kashuk JL, Moore EE, Millikan JS, Moore JB. Major abdominal vascular trauma—a unified approach. J Trauma. 1982;22:672–9.
48. Stone HH, Strom PR, Mullins RJ. Management of the major coagulopathy with onset during laparotomy. Ann Surg. 1983;197:532–5.
49. Lucas CE, Martin DJ, Ledgerwood AM, Hoschner J, McGonigal MD, Kithier K, Sardesai VM. Effect of fresh-frozen plasma resuscitation on cardiopulmonary function and serum protein flux. Arch Surg. 1986;121:559–64.

50. Harrigan C, Lucas CE, Ledgerwood AM. The effect of hemorrhagic shock on the clotting cascade in injured patients. J Trauma. 1989;29(10): 1416–21, discussion 1421–2.
51. Reed RL, Ciavarella D, Heimbach DM, Baron L, Pavlin E, Counts RB, Carrico CJ. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. Ann Surg. 1986;203:40–8.
52. Burch JM, Ortiz VB, Richardson RJ, Martin RR, Mattox KL, Jordan GL Jr. Abbreviated laparotomy and planned reoperation for critically injured patients. Ann Surg. 1992;215:476–83.
53. Cué JI, Cryer HG, Miller FB, Richardson JD, Polk HC Jr. Packing and planned reexploration for hepatic and retroperitoneal hemorrhage: critical refinements of a useful technique. J Trauma. 1990;30:1007–11.
54. Rotondo MF, Schwab CW, McGonigal MD, Phillips GR 3rd, Fruchterman TM, Kauder DR, Latenser BA, Angood PA. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma. 1993;35:375–82.
55. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest. 1988;94:1176–86.
56. Saggi BH, Sugerman HJ, Ivatury RR, Bloomfield GL. Abdominal compartment syndrome. J Trauma. 1998;45:597–609.
57. Balogh Z, McKinley BA, Cocanour CS, Kozar RA, Valdivia A, Sailors RM, Moore FA. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg. 2003;138:637–42.
58. Balogh ZJ, Lumsdaine W, Moore EE, Moore FA. Postinjury abdominal compartment syndrome: from recognition to prevention. Lancet. 2014; 384:1466–75.
59. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.
60. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15.
61. Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69:489–500.
62. MacLeod JB, McKenney LM, Cohn SM, and Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003; 55:39–44.
63. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127–32.
64. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet J. Acute traumatic coagulopathy: initiated by hypoperfusion. Ann Surg. 2007;245:812–8.

65. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011; 254194–200.
66. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost. 2011;9:182–188.
67. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887–96.
68. Martin M1, Oh J, Currier H, Tai N, Beekley A, Eckert M, Holcomb J An analysis of in-hospital deaths at a modern combat support hospital. J Trauma. 2009;66:S51–60.
69. Armand R and Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev. 2003;17:223–31.
70. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63:805–13.
71. Kashuk JL, Moore EE, Johnson JL, Haenel J, Wilson M, Moore JB, Cothren CC, Biffl WL, Banerjee A, Sauaia A. Postinjury life threatening coagulopathy: Is 1:1 fresh frozen plasma: Packed red blood cells the answer? J Trauma. 2008;65: 261–70.
72. Magnotti LJ, Zarzaur BL, Fischer PE, Williams RF, Jyers AL, Bradburn EH, Fabian, TC, Croce MA. Improved survival after hemostatic resuscitation: Does the emperor have no clothes? J Trauma. 2001;70:97–102.
73. Scalea Tm, Bochicchio KM, Lumpkins K, Hess JR, Dutton R, Pyle A, Bochicchio GV. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg. 2008;248:578–84.
74. Snyder CW, Weinberg, JA, McGwin G Jr., Melton SM, George RL, Reiff DA, Cross JM, Hubbard-Brown J, Rue, III, LW, Kerby JD. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma. 2009;66:358–64.
75. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR; Task Force for advanced bleeding care in trauma. Management of bleeding following major trauma: an updated European guideline. Crit Care. 2010;14:R52.
76. Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation. J Thromb Haemost. 2011;9: 1859–61.
77. Welsh JD, Stalker TJ, Voronov R, Muthard RW, Tomaiuolo M, Diamond SL, Brass LF. A systems approach to hemostasis: 1. The interdependence

of thrombus architecture and agonist movements in the gaps between platelets. Blood. 2014;124:1808–15.
78. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma. JAMA. 2015;313:471–82.
79. Moore HB, Moore EE, Gonzalez E. 1:2 is superior to1:1 JAMA. (in press).
80. Brenni M, Worn M, Brüesch M, Spahn DR, Ganter MT Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy. Acta Anaesthesiol Scand. 2010;54: 111–7.
81. Gonzalez E, Pieracci FM, Moore EE, Kashuk JL. Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography. Semin Thromb Hemost. 2010;36:723–37.
82. Johansson PI1, Stissing T, Bochsen L, Ostrowski SR Thrombelastography and thromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med. 2009;17:45–51.
83. Schöchl H1, Forster L, Woidke R, Solomon C, Voelckel W. Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate. Anaesthesia. 2010;65:199–203.
84. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.
85. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013;74:1575–86.
86. Pusateri AE, Weiskopf RB, Bebarta V, Butler F, Cestero RF, Chaudry IH, Deal V, Dorlac WC, Gerhardt RT, Given MB, Hansen DR, Hoots WK, Klein HG, Macdonald VW, Mattox KL, Michael RA, Mogford J, Montcalm-Smith EA, Niemeyer DM, Prusaczyk WK, Rappold JF, Rassmussen T, Rentas F, Ross J, Thompson C, Tucker LD; US DoD Hemorrhage and Resuscitation Research and Development Steering Committee. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39:121–6.
87. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77:811–7.
88. Tapia NM, Chang A, Norman M, Welsh F, Scott B, Wall MJ Jr, Mattox KL, Suliburk J. TEG-guided resuscitation is superior to standardized

MTP resuscitation in massively transfused penetrating trauma patients. J Trauma Acute Care Surg. 2013;74:378–85.

89. Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, Ghasabyan A, Wohlauer M Barnett CC, Bensard DD, Biffl WL, Burlew CC, Johnson JL, Pieracci FM, Stovall RT, Jurkovich GJ, Banerjee A, Silliman CC, Sauaia A. Goal-directed hemostatic resuscitation of trauma induced coagulopathy-A randomized clinical trial. Annals of Surg. 2015; doi:10.1097/sla.0000000000001608.

Contents

Contributors

Shahzaib Ahmad Barts and the London School of Medicine and Dentistry, St. Bartholomew's Hospital, Queen Mary University of London, West Smithfield, London, UK

Hasan B. Alam Section of General Surgery, University of Michigan, Ann Arbor, MI, USA

Ted Bambakidis Trauma Translational and Clinical Research Laboratory, Department of Surgery, University of Michigan Hospital, Ann Arbor, MI, USA

Case Western Reserve University School of Medicine, Cleveland, OH, USA

Anirban Banerjee, Ph.D. Department of Surgery and Trauma Research Center, University of Colorado and Denver Health Medical Center, Aurora, CO, USA

Christopher D. Barrett, M.D. Division of Trauma and Critical Care, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Susan C. Bock, Ph.D. Bioengineering Department, University of Utah, Salt Lake City, UT, USA

Nuala A. Booth, Ph.D. The Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

Jeannie L. Callum, B.A., M.D., F.R.C.P.C., C.T.B.S. Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

Andrew P. Cap, M.D., Ph.D., F.A.C.P. US Army Institute of Surgical Research, Houston, TX, USA

A. Casini Division of Angiology and Haemostasis, Faculté de Médecine, Hôpitaux Universitaires de Genève, Geneva, Switzerland

Faculté de Médecine, Service d'Angiologie-Hémostase, Hôpitaux Universitaires de Genève, Switzerland

Michael P. Chapman, M.D. Department of Surgery and Trauma Research Center, University of Colorado and Denver Health Medical Center, Aurora, CO, USA

Department of Surgery, Denver Health Medical Center, Denver, CO, USA

Mitchell Jay Cohen, M.D. UCSF Department of Surgery, San Francisco General Hospital, University of California, San Francisco, CA, USA

Scott L. Diamond, Ph.D. Department of Chemical and Biomolecular Engineering, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA, USA

Daniel Dirkmann, M.D. Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, Essen, Germany

Dominik F. Draxler, M.D. Molecular Neurotrauma and Haemostasis, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Australia

Joseph Emmerich, M.D., Ph.D. Unité de Médecine Vasculaire-Cardiologie, Centre de Diagnostic et de Thérapeutique—Hôtel Dieu, Université Paris Descartes, Paris, France

Charles T. Esmon, Ph.D. Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Massimo Franchini, M.D. Department of Hematology and Transfusion Medicine, Azienda Ospedaliera Carlo Poma, Mantova, Italy

Satoshi Gando, M.D. Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Todd M. Getz, Ph.D. Cellphire Inc., Rockville, MD, USA

Ruchika Goel Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

Divisions of Transfusion Medicine and Pediatric Hematology/Oncology, Departments of Pathology and Pediatrics, NewYork Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA

Eduardo Gonzalez, M.D. Department of Surgery and Trauma Research Center, University of Colorado School of Medicine, Aurora, CO, USA

Klaus Görlinger, M.D. Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, Essen, Germany

Tem International GmbH, Munich, Germany

Russell L. Gruen, M.B.B.S., Ph.D, F.R.A.C.S. National Trauma Research Institute, Melbourne, Australia

Alexander A. Hanke, M.D. Department of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany

Maureane Hoffman, M.D., Ph.D. Pathology and Laboratory Medicine Service, Durham Veterans Affairs Medical Center, Durham, NC, USA

Department of Pathology, Duke University Medical Center, Durham, NC, USA

John B. Holcomb, M.D., F.A.C.S. Department of Surgery, Division of Acute Care Surgery, Center for Translational Injury Research, University of Texas Health Science Center at Houston, Houston, TX, USA

Benjamin M. Howard, M.D., M.P.H. UCSF Department of Surgery, San Francisco General Hospital, University of California, San Francisco, CA, USA

Beverley J. Hunt Thrombosis and Haemophilia Centre, St Thomas' Hospital, London, UK

Pär I. Johansson, M.D., D.M.Sc, M.P.A. Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Division of Acute Care Surgery, Department of Surgery, Centre for Translational Injury Research (CeTIR), University of Texas Medical School at Houston, Houston, TX, USA

Marguerite R. Kelher Department of Surgery, University of Colorado Denver, Aurora, CO, USA

Sriram Krishnaswamy The Children's Hospital of Philadelphia, Abramson, Philadelphia, PA, USA

Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA

Shekhar Kumar The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Ryan A. Lawless, M.D. Department of Surgery, Division of Acute Care Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA

Karin Leiderman University of California Merced, Merced, CA, USA

Jerrold H. Levy, M.D., F.A.H.A., F.C.C.M. Duke University Medical Center, Duke University School of Medicine, Durham, NC, USA

Florea Lupu Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Marc Maegele, M.D., Ph.D. Department of Trauma and Orthopedic Surgery, Institute for Research in Operative Medicine (IFOM), Cologne-Merheim Medical Center (CMMC), University of Witten/Herdecke, Cologne, Germany